Hey Lupe,
Sorry, I should not have excluded this previous sentence from the report.
"We will revisit our model once the APIRx product line and developmental strategy has been fully integrated into the group."
This report is not a one-off, there will be quarterly updates.
My understanding is this Valuation is the Present Value and will be updated as the Clinical Trials progress.
On that basis, I should expect, that the valuation may gain a boost at the completion of Phase 1 - IHL-675 clinical trial which commences next week. Taking into account IHL-675's significantly larger TAM of
US$127 BLN compared to IHL-42X of
US$10.4BLN.Currently, the SP could go 3X to align with this conservative valuation.
per
@tossydog"Edisons Valuation: US$695.7m or US$11.42 per ADR. For the Aussie investors that is 66c."Good luck
@Lupe
